A Cross-Sectional Study to Assess and Correlate Serum Levels of Visfatin with Insulin Resistance amongst Newly Diagnosed Diabetes Mellitus, Metabolic Syndrome and Pre-Diabetes Patients

Visfatin is an adipocytokine which has been thought to play a role in pathogenesis of insulin resistance. Clarifying role of Visfatin along with its correlation to insulin resistance in Diabetes and Metabolic Syndrome (MS) patients would enhance our knowledge of this novel biomarker. It was a clinic based cross sectional study. Serum levels of Visfatin assessed randomly in 118 patients having diabetes, Pre-diabetes or metabolic syndrome, attending OPD in our institute. Visfatin levels measured along with BMI (Body Mass Index), Blood Pressure (BP), Lipids, Glucose, Insulin, Hs-CRP (High Sensitivity C Reactive Peptide) levels, Homeostatic model assessment is a method for insulin resistance (HOMA-IR) Indexes. One-way ANOVA and linear regression analysis were carried out using SPSS 23. Average Serum Visfatin (SV) levels were significantly different in Metabolic Syndrome (n=34, 9.50±8.22), Diabetic (n=43, 12.04±7.6) and Pre-Diabetic (n=41, 9.07±8.6) groups. Serum Visfatin shows a significant association with fasting blood sugar (p=0.009) and BMI (p=0.038) only in MS patients. Significant correlation not found between Visfatin and Insulin resistance (p=0.173) in either of 3 groups. In the present study, Serum Visfatin levels were not correlated with insulin resistance in metabolic, diabetic and pre-diabetic patients but Serum Visfatin showed significant association with fasting blood sugar and BMI in MS patients.